Vaccines 2017, 5(4), 35; https://doi.org/10.3390/vaccines5040035
Approaches and Perspectives for Development of African Swine Fever Virus Vaccines
1
European Union Reference Laboratory for ASF, Centro de Investigación en Sanidad Animal (INIA-CISA), 28015 Madrid, Spain
2
The Pirbright Institute (TPI), Surrey GU24 0NF, UK
3
ASTRE, University of Montpellier, CIRAD, INRA, F-34398 Montpellier, France
4
Istituto Zooprofilattico Sperimentale della Sardegna (IZS-Sardegna), 07100 Sassari, Sardinia, Italy
5
Faculdade de Medicina Veterinária (FMV-ULisboa), 1300-477 Lisbon, Portugal
6
Instituto Gulbenkian de Ciência (IGC), Rua Quinta Grande 6, 2780-156 Oeiras, Portugal
7
Centro de Biología Molecular Severo Ochoa (CBMSO-CSIC-UAM), C/ Nicolás Cabrera nº 1, Campus de Cantoblanco, 28049 Madrid, Spain
8
Institute for Research and Technology Food and Agriculture (IRTA), Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
9
OIE Reference Laboratory for ASF, Centro de Vigilancia Sanitaria Veterinaria (VISAVET), Universidad Complutense de Madrid, Avda. Puerta del Hierro, 28040 Madrid, Spain
*
Author to whom correspondence should be addressed.
Received: 1 September 2017 / Revised: 1 October 2017 / Accepted: 3 October 2017 / Published: 7 October 2017
(This article belongs to the Special Issue Vaccines against Emerging and Reemerging Viral Diseases of Humans and Animals)
Abstract
African swine fever (ASF) is a complex disease of swine, caused by a large DNA virus belonging to the family Asfarviridae. The disease shows variable clinical signs, with high case fatality rates, up to 100%, in the acute forms. ASF is currently present in Africa and Europe where it circulates in different scenarios causing a high socio-economic impact. In most affected regions, control has not been effective in part due to lack of a vaccine. The availability of an effective and safe ASFV vaccines would support and enforce control–eradication strategies. Therefore, work leading to the rational development of protective ASF vaccines is a high priority. Several factors have hindered vaccine development, including the complexity of the ASF virus particle and the large number of proteins encoded by its genome. Many of these virus proteins inhibit the host’s immune system thus facilitating virus replication and persistence. We review previous work aimed at understanding ASFV–host interactions, including mechanisms of protective immunity, and approaches for vaccine development. These include live attenuated vaccines, and “subunit” vaccines, based on DNA, proteins, or virus vectors. In the shorter to medium term, live attenuated vaccines are the most promising and best positioned candidates. Gaps and future research directions are evaluated. View Full-TextKeywords:
African swine fever; vaccine; immunology; vaccine gaps
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Arias, M.; De la Torre, A.; Dixon, L.; Gallardo, C.; Jori, F.; Laddomada, A.; Martins, C.; Parkhouse, R.M.; Revilla, Y.; Rodriguez, F.-M.; Sanchez-Vizcaino. Approaches and Perspectives for Development of African Swine Fever Virus Vaccines. Vaccines 2017, 5, 35.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Related Articles
Article Metrics
Comments
[Return to top]
Vaccines
EISSN 2076-393X
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert